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Abstract
Glucose is an essential fuel for cell survival and its availability limits aberrant cellular proliferation. We have hypothesized
that specific cancer mutations regulate metabolic response(s) to glucose deprivation (GD). By means of somatic knock-in
cellular models, we have analyzed the response to glucose deprivation in cells carrying the frequent
delE746-A750EGFR,
G13DKRAS or
E545KPIK3CA cancer alleles. We demonstrate that, in mammary epithelial cells, glucose has an essential
antioxidant function and that these cells are very sensitive to GD. Conversely, isogenic cells carrying the
delE746-A750EGFR or
the
E545KPIK3CA, but not the
G13DKRAS allele, display high tolerance to GD by stimulating the expression of anti-oxidant
genes (MnSOD and catalase). This adaptive transcriptional response is mediated by the activation of WNT/b-catenin and
FOXO4 signalling. Our data highlights a new functional synergism between oncogenic EGFR and PIK3CA with WNT/b-
catenin conferring high tolerance to oxidative stress generated by nutrient deprivation.
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Introduction
Glucose is a fundamental cellular fuel for the generation of ATP
and NADH through glycolysis and the mitochondrial oxidative
phosphorylation; it is also an essential component of the pentose
phosphate shunt pathway (PPP) that leads to the production of
NADPH used to synthesize reduced glutathione, a potent
intracellular antioxidant. Thus, glucose deficit is likely to produce
energetic dysfunction and oxidative stress.
Glucose limitation is a common stress during tumor progression:
glucose concentration acts as an energetic barrier against the
aberrant cellular proliferation of pre-malignant cells [1]; more-
over, an energetic deficit occurs in certain areas of solid tumors
where glucose and oxygen deficiencies are generated by the
unstable tumor microenvironment or ischemia [1],[2]. Thus,
cellular adaptation to sub-optimal nutrients concentrations
appears as a relevant phenotype that cancer cells acquire during
tumor progression. A key open issue is to identify the specific
genetic alteration(s) that drive the metabolic adaptation of cancer
cells to glucose deficiency. Recently, the
G13DKRAS and
V600EB-Raf
oncogenes have been associated with a resistance to low glucose
and
G13DKRAS mutations occur in cells upon selection in low
glucose environment [3]. In addition, tumors carrying deletions of
the tumor suppressor PTEN, a lipid phosphatase, are resistant to
caloric restriction in vivo [4].
Epidermal Growth Factor Receptor (EGFR) and the phospha-
tidylinositol 3-kinase (PI3K), are oncogenes frequently mutated in
human cancers. PI3Ks are a family of lipid kinases that
phosphorylate the 3-OH group on phosphatidylinositols in the
plasma membrane. This leads to the recruitment to the cell
membrane and activation of the protein Ser/Thr-kinase AKT.
The PI3K/AKT signaling cascade is critical in cancer develop-
ment since it controls the activity of fundamental cell fate
regulators and promotes cell survival and growth. Activating
mutations in PIK3CA, the gene encoding the p110a catalytic
subunit or inactivating mutations of PTEN, have been identified in
a variety of solid tumors [5], [6], including colorectal, breast and
endometrial cancers. Notably, three recurrent oncogenic ‘‘hot-
spot’’ mutations include the majority of somatic PIK3CA muta-
tions. Two of these mutations, the E542K and the E545K, occur
in the helical domain, and the third mutation, H1047R, affects the
kinase domain [7]. All three mutations result in enhanced lipid
kinase activity.
EGFR is a receptor tyrosine kinase involved in the control of
DNA synthesis, cell proliferation, migration and adhesion [8].
Upon binding with extracellular ligands and dimerization, EGFR
leads to the activation of multiple intracellular signaling pathways,
such as the PI3K/AKT, the MEK/ERK and the JAK/STAT
pathways. EGFR overexpression by gene amplification or by
EGFR activation have been associated with several cancers,
including lung and breast cancer and glioblastoma multiforme [9],
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37526[10]. A specific point mutation L858R- and short in-frame
deletions in exon 19 account for approximately 90% of the
mutated cases [11]. The in frame deletion E746-A750 in exon 19
induces a ligand independent EGFR dimerization and activation
[12].
T od a t e ,w eh a v el i m i t e di n f o r m a t i o na b o u tt h ei n t e r f e r e n c eo ft h e
specific cancer mutations of EGFR and PIK3CA with metabolic
responses of cells exposed to glucose deprivation. To gather
information on this issue, we have investigated the cellular response




G13DKRAS mutations. For these studies, we
have implemented a panel of isogenic cell lines generated by targeted
homologous recombination to introduce (knock-in) a cancer allele in
the genome of human somatic cells [13]. The derivative cells express
the cancer alleles under the control of their endogenous promoter, thus
allowing the study of the mutated proteins under physiological
conditions relative to the expression levels and transcriptional
regulation.
Our studies reveal that, in mammary epithelial cells, GD induces a
drop in the ATP content, a significant reduction of the cellular
antioxidant power resulting in oxidative stress and ultimately, cell
death. In contrast, isogenic cells carrying
delE746-A750EGFR
or
E545KPIK3CA alleles, upon GD, engage antioxidant strategies, by
increasing the expression of MnSOD and catalase genes that attenuate
the oxidative stress. The activation of such adaptive transcriptional
response is mediated by WNT signals through the action of b-catenin





confer resistance to GD
We implemented a panel of isogenic cells generated by targeted
homologous recombination (Knock-in) of
delE746-A750EGFR,
E545KPIK3CA or
G13DKRAS cancer alleles in immortalized human
mammary epithelial cells (HME) [13]. The expression of cancer
alleles affects the regulation of downstream signaling pathways as
confirmed by serum deprivation experiments (Figure S1): in fact,
serum starvation elicited a dose-dependent reduction of phos-
phorylation of AKT(Ser473), of EGFR(Tyr1068), and ERK1/
2(Thr202/Tyr204) in wild type HME cells, while isogenic clones,
expressing the oncogenes, did not specifically reduce the
phosphorylation of the same substrates (Figure S1).
We then investigated cell survival in response to GD of wild type
and the isogenic lines expressing the mutant alleles. Prolonged GD
affects cell cycle and cell viability [14,15]. FACS analysis revealed




proteins were resistant to GD. In contrast, the presence of
G13DKRAS allele specifically led to higher sensitivity to GD
(Figure 1). Similar results were observed in independently
generated isogenic HME clones (Figure S2). To rule out that the
observed differences in cell viability between wild type cells and
the isogenic derivatives were an artefact due to the procedures
used to generate the cellular model, we analyzed isogenic HME
cells generated through the homologous recombination of the wild
type alleles of EGFR or PIK3CA genes, here referred to as
PIK3CA_cnt and EGFR_cnt. GD induced cell death of these
control cells as well as in wild type HME cells (Figure S2). These
data indicate that resistance to GD-induced death is specifically




The oncogenic variants control ATP levels and GSH/GSSG
ratio in response to GD
Glucose is a fundamental cellular energy supply for ATP
production. Moreover, glucose also fuels the pentose phosphate
pathway (PPP), the metabolic process that stimulates the
anabolism and generates cellular NADPH and supports the
production of reduced glutathione (GSH), the most important
cellular antioxidant. Thus, GD is expected to induce both
energetic and oxidative stress. To evaluate the metabolic effects
elicited by GD in HME wild type and isogenic clones, we
measured total ATP content and the ratio between reduced and
oxidized glutathione (GSH/GSSG ratio) following GD. Time
course analysis revealed that wild type HME and isogenic clones
carrying
G13DKRAS or
E545KPIK3CA oncogenes displayed a
significant time-dependent reduction of the ATP levels following
GD; in contrast, isogenic clones carrying the
delE746-A750EGFR
retained 100% of ATP content up to 10 hours after treatment
(Figure 2A). Moreover, GD induced a significant reduction of the
GSH/GSSG ratio in wild type HME cells, in
G13DKRAS-carrying
cells and in isogenic control cells but NOT in clones carrying
delE746-A750EGFR and
E545KPIK3CA alleles (Figure 2B). These data
show that glucose is essential in mammary epithelial cells to
maintain redox homeostasis and that some oncogenic mutations
specifically compensate redox unbalance induced by glucose
deprivation
GD induces cell death through oxidative stress
The results in Figure 2 indicated that, in wild type cells, GD
elicited a drop of the intracellular GSH/GSSG ratio that reduced
the intracellular antioxidant power and induced a redox stress. To
analyze the relevance of the oxidative stress generated by GD, we
measured the effects of antioxidants on GD-induced cell death.
Pre-treatment of wild type HME cells with N-Acetyl-L-Cysteine,
which increases the GSH pool and enhances ROS scavenging,
prevents cell death induced by GD (Figure 3A). Notably, under the
same conditions, pre-treatment of the cells with sodium pyruvate,
did not affect GD-induced cell death, indicating that the energetic
stress, resulting from ATP drop, was indeed not the major driver
of GD-induced cell death (Figure 3A). As NAC contributes also to
H202-scavenging by increasing the GSH intracellular pool, we
assessed the relevance of H202 concentration in GD-induced cell
death. Our data show that treatment with purified human
catalase, an H202-scavenger enzyme, inhibited GD-induced cell
death in wild type HME cells (Figure 3B). Taken together, these
data indicate that glucose has an essential antioxidant role in
mammary epithelial cells.
AMPKa is a sensor of GD-induced oxidative stress
The AMP-activated protein kinase (AMPK) is a key molecular
sensor and regulator of the cellular response to glucose deprivation
[16,17]. To further understand to what extent glucose deprivation
elicits a metabolic stress in wild type HME and in isogenic clones
carrying oncogenes, we studied the activation of AMPKa by
measuring the phosphorylation of AMPKa(T172), a specific
marker of kinase activation [16,17]. Our data show that
AMPKa(T172) was highly phosphorylated upon 10 hours of GD
in wild type cells and
G13DKRAS expressing cells, whereas this
phosphorylation was attenuated in isogenic HME cells carrying
the
E545KPIK3CA or the
delE746-A750EGFR cancer alleles (Fig. 4A).
Similar results were observed in independently generated isogenic
HME clones (Figure S3A). Moreover, the observed attenuation
was specifically induced by the oncogenes, since control cells
displayed a robust activation of AMPKa(T172) phosphorylation
Adaptation to Glucose Deprivation by Oncogenes
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phosphorylation by cancer alleles was further confirmed by time
course analysis of AMPKa(T172) phosphorylation after GD
(Figure 4B).
AMPK is a general stress sensor that can be activated by AMP
or by multiple intracellular signals such as calcium [18], free fatty
acids [19] and reactive oxygen species (ROS) [20]. To link the
oxidative stress induced by GD to AMPK activation, we pre-
treated wild type HME cells before GD with the antioxidant NAC
and we analyzed the AMPKa(T172) phosphorylation. Immuno-
blot analysis of protein extracts shows that NAC attenuated GD-
induced phosphorylation of AMPK (Figure 4C). Similar results
were obtained by pre-treating the cells with a SOD mimetic
compound that is able to neutralize cellular superoxide (Figure 4D).
Finally, pre-treatment of wild type HME cells with purified human
catalase reduced also GD-induced AMPK phosphorylation
(Figure 4E). The antioxidant activity of glucose is dependent on
its ability to stimulate G6PDH activity and to support the PPP: in
fact, the inhibition of G6PDH by the specific inhibitor 6-
aminonicotinamide (6AN) was sufficient to induce oxidative stress
and to phosphorylate AMPK in the presence of glucose. 6AN-
induced AMPKa phosphorylation was controlled by ROS since it
was inhibited by the pre-treatment of cells with NAC (Figure 4F).
These data show that GD induces a significant oxidative stress that
contributes to AMPK phosphorylation. In cells carrying activated
oncogenes, this circuitry is not efficient. It is possible that the
oxidative stress is attenuated in these cells, as suggested by Figure 2.
However, it is also likely that AMPK is inhibited by oncogenic
ERK-dependent signals through increased phosphorylation of the
major AMPK activating kinase, LKB1, which, when phosphor-
ylated at Serine 428, inhibits AMPK [21,22]. To discriminate
between these two possibilities we measured the phosphorylation
of LKB1(S428) after GD in wild type HME and isogenic clones.
Western blot analysis showed that LKB1 levels were comparable
in wild type HME and in isogenic clones (Figure 5A). GD induced
a reduction of total LKB1 protein both in wild type and isogenic
cells carrying
E545KPIK3CA or
delE746-A750EGFR alleles. By using
specific antibodies against phospho-Ser428LKB1, we found that
GD reduced phospho-LKB1(S428) levels in wild type HME cells
as well as in isogenic clones (Figure 5A). Moreover, the treatment
with AICAR, an AMP analogue, efficiently induced AMP-
Ka(T172) phosphorylation in wild type HME cells as well as in
isogenic clones carrying the
delE746-A750EGFR and
E545KPIK3CA
alleles (Figure 5B). Importantly, AICAR treatment, in contrast to
GD, did not downregulate LKB1 and phospho-LKB1(S428) levels
(Figure 5B), supporting the hypothesis that other mechanisms, in
addition to the AMP/ATP ratio, control the LKB1/AMPK
complex after exposure to GD. Collectively, these data demon-
strate that mammary epithelial cells expressing the
delE746-
A750EGFR and the
E545KPIK3CA oncogenes have a functional
AMP/LKB1/AMPKa sensor circuitry and that the attenuation of
AMPK activation depends on the control of oxidative homeostasis.
delE746-A750EGFR and
E545KPIK3CA oncogenes specifically
induce antioxidant enzymes in response to GD
A simple mechanism explaining the resistance of oncogene-
carrying cells to GD is the production of endogenous glucose, for
example from glycogen storage. Determination of total glycogen
levels indicated that HME cells carrying the
delE746-A750EGFR and
E545KPIK3CA alleles contain higher total glycogen compared to
isogenic wild type or control HME (Figure 6). Notably, 309 after
GD, we observed a rapid and strong decrease of glycogen content
in both control and oncogene-carrying cells; after 30 minutes of
GD, glycogen content declined in all cell lines, although steeper in
oncogene-carrying cells than controls. Also, the pharmacological
inhibition of glycogenolysis with a glycogen phosphorylase
Figure 1. HME cells carrying the
delE746-A750EGFR or the




G13DKRAS alleles were glucose-starved (GD) for the indicated hours and the percentage of dead cells
were quantified by FACS analysis of propidium iodide positive cells. Graphs report the average of three independent experiments 6 SD (t-test,
**p,0.05 or ***p,0.001, Not treated Vs GD-treated cells). The diagrams are representative of a FACS analysis performed 24 hours after GD.
doi:10.1371/journal.pone.0037526.g001
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oncogene-carrying cells after GD (data not shown). These data
indicate that glycogen storage was not responsible for the
resistance to GD of oncogene-carrying cells.
We next tested the possibility that resistance to GD may depend
on antioxidant strategies. An efficient antioxidant response relies
on the rapid changes of expression of antioxidant enzymes. To this
end we analyzed the expression of relevant antioxidant genes.
Quantitative real time-PCR analysis revealed that HME cells
expressing the
delE746-A750EGFR or
E545KPIK3CA alleles showed a
two fold increase of Manganese Superoxide dismutase (MnSOD) mRNA
compared to wild type cells (Figure 7A). Moreover, HME clones
expressing selectively EGFR and PIK3CA oncogenes displayed a
robust expression of Manganese Superoxide dismutase (MnSOD) and
catalase mRNAs following GD (Figure 7B). On the other hand,
G13DKRAS-expressing cells did not stimulate the expression of these
antioxidant genes (Figure 7B). Western blot analysis on total
protein extracts confirmed that oncogene-carrying clones have
significant higher levels of MnSOD protein compared to wild type
cells (Figure S4).
Figure 2. ATP content and GSH/GSSG ratio in wild type or oncogene-expressing HME cells after glucose deprivation. (A) Total ATP
content after GD in wild type HME cells and isogenic clones carrying
delE746-A750EGFR,
E545KPIK3CA or
G13DKRAS cancer alleles. At the indicated time, cells
were harvested and the total ATP content was analyzed; ATP amount was normalized for the number of nuclei. Results (mean 6 SD, n=3) are
expressed as percentages of the ATP amount respect to T=0. WTp: wild type HME parental cells; PI3K_cnt and EGFRdel_cnt are HME control cells
carrying the wild type alleles obtained through somatic homologous recombination (see text for details). (B) Reduced and oxidized glutathione ratio
(GSH/GSSG) in wild type, control and oncogenes-carrying cells after GD. Cells were glucose starved for 10 hours, and then the GSH/GSSG ratio was
measured. Results report the average of eight independent experiments 6 SD (t-test, **p,0.01, Not treated Vs GD-treated cells. ns: not significant).
doi:10.1371/journal.pone.0037526.g002
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driven responses to GD
To find the specific transcriptional network induced by the
oncogenes following GD, we have searched for transcription
factors that stimulate Catalase and MnSOD gene expression. These
genes are known targets of the Forkhead transcription factors
(FOXOs) [23,24] and b-catenin, a key effector of the WNT
pathway [25,26]. Although the PI3K/AKT-dependent signaling
has been recognized as a negative regulator of FOXOs, FOXO4
and b-catenin proteins can accumulate into nucleus and act as
transcriptional sensors of oxidative stress independently of the
presence of growth factors [26,27]. Based on these observations,
we studied the regulation of b -catenin and FOXO4 after GD in
wild type HME cells and in isogenic clones carrying oncogenes.
Since stability and nuclear localization of b-catenin are negatively
controlled by a GSK3b kinase-dependent phosphorylation of
Ser33,37 and Thr41 residues of b-catenin, we assayed the
phosphorylation of these residues in response to GD. Western
blot with specific antibodies indicated that phosphorylation of the
Ser33,37 and Thr41 of b-catenin was rapidly inhibited in response
to GD in oncogenes-carrying cells but not in wild type cells
(Figure 8A and 8B). Ser33,37 and Thr41 phosphorylation of b-
catenin in wild type cells under GD was mainly dependent on
GSK3b kinase activity since exposure to the GSK3b inhibitor,
lithium chloride, eliminated the phosphorylation of these residues
of b-catenin (Figure 8A). These data suggest that oncogenic EGFR
and PI3K selectively inhibit GSK3b during GD. Accordingly,
immunoblot analysis showed that the levels of phosphorylated
GSK3b(S9), an inhibitory site phosphorylated by AKT, was
higher in oncogene-expressing cells exposed to GD (Figure 8C).
Since active b-catenin is targeted to the nucleus, we monitored
b-catenin nuclear accumulation in response to GD. Our data show
that HME cells carrying-oncogenes accumulate significant nuclear
b-catenin in response to GD compared to isogenic wild type cells
(Figure 8D). To further document the activation of b-catenin, we
performed immmunoflorescence analysis by using specific anti-
bodies recognizing active, not-phosphorylated, b-catenin. Our
data indicate that nuclear localization of active b-catenin is
increased in HME cells expressing the
delE746-A750EGFR or the
E545KPIK3CA alleles compared to the isogenic wild type cells; after
exposure to GD, active b-catenin robustly accumulate into nucleus
of oncogenes-carring cells, more efficiently than wild type cells.
These data demonstrate that the
delE746-A750EGFR and the
E545KPIK3CA proteins stimulate b-catenin activation and target-
ing to the nucleus following exposure to glucose deprivation
(Figure 8E). We next analyzed the expression of FOXO4: western
blot analysis demonstrated that oncogenes-carrying cells displayed
a 2-fold increase of nuclear FOXO4 compared to wild type cells,
independently of GD (Figure 8D); this effect was specific to
FOXO4, since nuclear FOXO1 was indeed reduced in cells
carrying activated EGFR and PI3K pathways (Figure 8D).
However, we observed a reduction of nuclear FOXO1 in response
to GD in wild type cells but not in isogenic clones carrying
oncogenes, suggesting that oncogenic EGFR and PIK3CA also
stabilized FOXO1 in response to GD (Figure 8D).
To further investigate whether FOXO4 and b-catenin cooper-
ate to activate the expression of antioxidant genes in response to
GD in HME cells, we used a MnSOD promoter reporter assay
previously described [25,26]. b-catenin was able to enhance
FOXO4-dependent and independent transcription of the MnSOD
promoter in wild type HME cells under GD (Figure 8F, left
graph), indicating that MnSOD promoter can be also activated by
stimuli FOXO4-independent, but b-catenin-dependent (Figure 8F,
left graph). As expected, MnSOD promoter reporter assay was
significantly stimulated in HME cells carrying the
delE746-A750EGFR
or the
E545KPIK3CA oncogenes compared to wild type cells
(Figure 8F, right graph).
Figure 3. NAC and Catalase confer resistance to GD-induced cell death. (A) Antioxidant but not pyruvate treatment inhibits GD-induced cell
death. Wild type HME cells were glucose starved for 36 hours with or without 5 mM N-acetyl-L-Cysteine or sodium pyruvate at the indicated
concentrations. The percentage of dead cells was quantified by FACS as in Fig 1. The data are derived on the average from at least three independent
experiments 6 SD (t-test, **p,0.05 or **p,0.001). (B) Purified human catalase treatment induces cellular resistance to GD-induced cell death. Wild
type HME cells were glucose starved for 36 hours with or without 12 hours of pre-treatment with purified human catalase (600 U/ml) or heat
inactivated catalase (HI). The percentage of dead cells was quantified as in (A).
doi:10.1371/journal.pone.0037526.g003
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mammary epithelial cells exposed to GD
To functionally link the GSK3b and b-catenin axis with the
response to glucose deprivation, we co-expressed b-catenin and
FOXO4 in wild type HME cells and monitored cell death after
48 hours of exposure to GD. Our data demonstrate that the
expression of b-catenin and FOXO4 improves resistance to GD of
wild type HME cells (Figure 9A). Moreover, we also demonstrate
that the expression of the GSK3b(K85A) mutant - a GSK3b
kinase dominant negative - protects wild type cells from GD-
induced death (Figure 9A). Expressing wild type GSK3b kinase
did not induce the protective effect. These data underline the
importance of the constitutive, oncogenic activation of EGFR/
Figure 4. GD-induced oxidative stress control AMPKa activation. (A) Wild type HME or isogenic cells carrying the indicated cancer alleles
were glucose deprived for 10 hours and equal amounts of protein lysates were assayed by immunoblot with the indicated antibodies. The graph




G13DKRAS alleles were glucose starved for the indicated time. Total proteins were analyzed by
immunoblot as indicated. The graph reports the densitometry analysis of the pAMPKa/AMPKatotal. Wild type: black square;
E545KPIK3CA: white square;
delE746-A750EGFR: gray square;
G13DKRAS: dark gray square. Data are representative of three independent experiments that gave similar results. (C and D)
Treatment with antioxidants attenuates GD-induced pAMPKa(T172). Wild type HME cells were pre-treated with N-acetyl-L-Cysteine (C) or mimetic
SOD (D) 1 hour before glucose starvation. Proteins extracts were analyzed by immunoblot with anti-pAMPKa(T172) and anti-AMPKa antibodies. The
graph reports the densitometry analysis of the pAMPKa/AMPKatotal; average from at least three independent experiments 6 SD are reported as
relative fold to not-treated cells. (E) Catalase treatment reduces GD-induced pAMPKa. Wild type HME cells were treated with catalase at the indicated
concentrations and harvested after 3 hours of GD. Equal amount of protein lysates were analyzed by immunoblot. (F) G6PDH inhibitor induces
AMPKa(T172) phosphorylation through ROS generation. Wild type HME cells were treated as indicated with 6-AN in glucose- and serum-containing
media (left panels) or were pre-treated with NAC before 6-AN treatment (right panels) and total protein extracts were analyzed by immunoblot with
anti-pAMPKa(T172) and anti-AMPKa antibodies. Histograms in E and F report the densitometry analysis of the pAMPKa/AMPKatotal. Average from at
least three independent experiments 6 SD were plotted.
doi:10.1371/journal.pone.0037526.g004
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GD.
To directly link the MnSOD expression with resistance to GD,
we generated wild type HME cell lines stably expressing the
antioxidant MnSOD enzyme. Upregulation of MnSOD expres-
sion was sufficient to protect the cells from GD-induced cell death
(Figure 9B). These results indicate that the increased MnSOD
expression is an important component of oncogene-induced
resistance to GD in cells carrying the
delE746-A750EGFR or
E545KPIK3CA cancer alleles.




significantly increases nuclear b-catenin pool in response to GD
and enhances b-catenin- and FOXO4-dependent expression of
genes involved in antioxidant stress response.
Discussion
An essential antioxidant role of glucose in mammary
epithelial cells
In mammary epithelial cells the metabolic checkpoint for
glucose concentration is based on ROS homeostasis. GD induces a
significant reduction of the GSH/GSSG ratio, a severe oxidative
stress and, ultimately, cell death. GSH level is controlled by PPP
and depends on activation of NADPH oxidase and SOD.
Activation of G6PDH and glutathione peroxidase in combination
with NADPH oxidase and SOD maintains stable GSH levels [28].
In the absence of glucose and under low ATP levels, this process is
inefficient and the GSH/GSSG ratio decreases, leading to rise of
ROS levels. ROS generated by GD induce the phosphorylation
and activation of AMPKa. Similarly, 2-Deoxy-D-glucose, a not-
hydrolysable glucose analogue, stimulates AMPKa(T172) phos-
phorylation by a ROS-mediated mechanism (LC, unpublished
data and [29]). Thus, ROS generated by GD act as metabolic
intermediates able to activate AMPK. HME cells expressing the
Figure 5. Cells expressing
delE746-A750EGFR or
E545KPIK3CA cancer alleles have functional AMP/LKB1/AMPK sensor machinery. (A)
Regulation of LKB1 kinase in HME cells after GD. Equal amounts of total protein lysates of wild type or isogenic cells were analyzed by immunoblot
with antibodies against LKB1 and pLKB1(Ser428); b-actin was used as loading control. The graph indicates the densitometry analysis of the data
derived from at least three independent experiments (t-test, *p,0.05, Not treated Vs GD-treated cells. ns: not significant). (B) AICAR treatment
increases pAMPKa(T172) in wild type and in oncogene-carrying cells and does not influence LKB1 expression. The indicated isogenic cell lines were
treated for 2 hours with 1 mM AICAR and total protein lysates were analyzed by immunoblot with the indicated antibodies.
doi:10.1371/journal.pone.0037526.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37526delE746-A750EGFR and
E545KPIK3CA mutants are resistant to GD-
generated oxidative stress and show reduced AMPK activation.
We have found that the resistance strategies involve, at least in
part, the activation of antioxidant enzymes such as MnSOD and
catalase. The upregulation of MnSOD is adaptive since it
increases the ROS neutralization as well as the rate of GSH
production [28]. High basal levels of MnSOD expression has been
reported associated to invasive and highly aggressive breast cancer
[30,31] and this may indicate the high ability of tumor cell to
adapt to nutrient deprivation. Since the EGFR and PIK3CA are
among the most frequently activated oncogenes in cancer, we
suggest that the specific anti-oxidant transcriptional program
driven by these oncogenes protects and favours the selection of the
cells carrying the mutated proteins. Our data offer a mechanistic
explanation for the selection and the reproductive success of such
cells under environmental metabolic stress. We suggest that
MnSOD and catalase expression may represent a common anti-
oxidant mechanism in pre-cancerous cells harbouring activating
mutation of the EGFR- and PI3K-dependent pathways. The
ability to tune metabolic enzymes and pathways to survive under
nutrient stress may represent a relevant and common phenotype of
cancer cells. In this framework, we believe that also the
hypertrophy of the serine synthesis pathway in breast cancer cells
[32,33] reflects the ability of cancer cells to continuously adapt to
different metabolic needs.
Oncogenes and glucose metabolism: not just a matter of
addiction in tumor progression
Specific metabolic changes occur during tumor development and
allow cellular adaptation to the unstable tumor microenvironment.
One of the most prominent metabolic changes in cancer cells is the
high glycolytic rate in the presence of oxygen, a phenomenon known as
the Warburg effect [1,34,35]. As consequences of the Warburg effect,
cancer cells show increased glucose needs and higher sensitivity to
glucose deprivation compared to normal cells, a phenomenon known
as glucose addiction [35,36]. In cancer cells, the expression of
constitutive active AKT [37], [38], KRAS [3,39,40] or the activation
of the mTOR pathway [14,41] has been associated with an increased
Warburg effect and higher sensitivity to glucose deprivation. Here, we
demonstrate that in not-transformed mammary epithelial cells GD
elicits cell death and that the expression of oncogenic EGFR and
PIK3CA confers resistance rather than sensitivity to glucose depriva-
tion. Moreover, we did not observe a significant increase of the
glycolytic index in oncogenes-carrying clones compared to wild type
HME (data not shown). This apparent contradiction might be
explained by different experimental and biological conditions: i) the




oncogenes; ii) the endogenous expression levels of the oncogenic allele
in the knock-in models compared with the constitutive transgenic over-
expression;iii) tissue-specificmetaboliceffects ofeachcancermutations;
iv) the use of pre-cancerous cells instead of transformed cancer cells that
could, indeed, carry on additional mutations and whose combination
could generate more complex metabolic phenotypes.
The observed oncogene-induced resistance to glucose depriva-
tion in epithelial cells indicates that, during neoplastic progression,
cancer cells may display a variable degree of glucose addiction,
depending on the tumor stage: advanced tumors may show an
increased glycolytic rate and glucose addiction as adaptive
strategies that support acidosis, hypoxic growth and invasion.
We suggest that pre-cancerous cells have an opposite strategy,
since glucose addiction represents a strong metabolic Achilles’ heel
that limits the progression of cells carrying a functional AMPK,
which represents an important metabolic checkpoint controlling
cell fate under glucose deprivation [14]. In this perspective,
glucose availability represents an intrinsic barrier that restricts
aberrant proliferation of mammary cells. Oncogenic activation of
EGFR or PI3K pathways selects and drives cellular clones able to
surmount such metabolic barriers and to survive under sub-
optimal microenvironment conditions.
Enhanced nuclear b-catenin and FOXO4 signalling by
oncogenic EGFR and PIK3CA
We have documented a positive feedback between the
oncogenic EGFR and PI3K pathways with the FOXO4 and b-
catenin signals in response to glucose deprivation. The role of
FOXO proteins as tumor suppressors has been largely recognized
and has been associated with their ability to promote cell cycle
arrest [42]. Here, we propose that FOXO4, specifically activated
by b-catenin, promotes cell resistance to oxidative metabolic stress
and survival of oncogenes-carrying cells. This dual function of
FOXOs may depend on a complex code of post-translational
modifications and interacting co-activators that differentially
control FOXOs functions under different conditions and in a
tissue specific manner [42,43]. There is evidence indicating an
evolutionary conserved interaction between FOXO4 and b-
catenin induced by starvation and enhanced by oxidative stress
that drives the expression of antioxidant enzymes, such as
MnSOD [26]. Along with these observations, our findings support
the conclusion that b-catenin is a transcriptional co-activator that
switches on FOXO target genes under nutrient stress and
promotes cell survival.
We show that somatic mutations frequently observed in breast
cancer lead to b-catenin activation: this observation strengthens
emerging data outlining the relevance of the b-catenin activation
in breast cancer [44,45] and the crosstalk between EGFR and
WNT signals in breast cancer development [46]. One mechanism,
Figure 6. Total glycogen content in oncogene-expressing HME
cells after glucose deprivation. Total glycogen content after GD in
wild type HME cells and isogenic clones carrying
delE746-A750EGFR,
E545KPIK3CA or
G13DKRAS cancer alleles. At the indicated time, cells were
harvested and total glycogen content was analyzed. Results (average of
three independent experiments 6 SD) are expressed as glycogen
content normalized for protein mass. WT: wild type HME cells;
PIK3CA_cnt and EGFR_cnt are HME control cells carrying the wild type
alleles (see text for details).
doi:10.1371/journal.pone.0037526.g006
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37526Figure 7. GD induces the transcription of antioxidant enzymes in cells carrying the
delE746-A750EGFR or the
E545KPIK3CA alleles. (A)
Upregulation of MnSOD expression by oncogenes. Total RNA was harvested from wild type HME or the indicated isogenic clones. The expression of
MnSOD normalized to b-actin mRNA was analyzed by quantitative real time PCR. Data (means 6 SD) indicate fold relative to wild type cells. (B) Wild
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37526type or the indicated isogenic HME cells were glucose starved and RNA was harvested at the indicated time points. The relative expression of the
MnSOD or Catalase genes, normalized to b-actin mRNA, was analyzed by quantitative real time PCR. Data show means 6 SD.
doi:10.1371/journal.pone.0037526.g007
Figure 8. Upregulation of FOXO4 and b-catenin by EGFR and PIK3CA oncogenes contributes to MnSOD expression in response to
GD. (A) GD controls b-catenin phosphorylation and stability. Wild type HME or oncogene carrying cells were glucose deprived for 4 hours in the
presence or not of lithium chloride and equal amounts of proteins were assayed by immunoblot. The anti-pb-catenin antibody recognizes the
phosphorylated Ser33,37 and Thr41 residues of b-catenin. The graph reports the densitometry analysis of the pb-catenin/b-catenin (gray bars) and
the b-catenin/b-actin (black bars). (B) Time course analysis of b-catenin phosphorylation after GD. HME clones were GD for the indicated time. Total
proteins were analyzed by immunoblot as indicated. The graph reports the densitometry analysis of pb-catenin/b-catenin. (C) Regulation of GSK3b
phosphorylation in response to GD. The indicated HME clones were glucose starved for 6 hours and total protein extracts were analyzed by
immunoblot as indicated. pGSK3b antibody recognizes specifically the phospho-Ser9 residue of GSK3b. The graph reports the densitometry analysis
of the pGSK3b/b-catenin signals. (D) Regulation of nuclear b-catenin and FOXO4 accumulation by oncogenes in response to GD. Wild type HME or
isogenic cells carrying
delE746-A750EGFR or
E545KPIK3CA cancer alleles were glucose starved for 5 hours and equal amounts of nuclear protein extracts
were assayed by immunoblot as indicated. MCM7 antibody recognizes the nuclear minichromosome maintenance protein 7 and is here used as
loading control. Graphs report the densitometry analysis of indicated protein/MCM7 signals ratio. Results report the average of three independent
experiments 6 SD (t-test, **p,0.01; *p,0.05). (E) Intracellular localization of active b-catenin (ABC) after GD exposure. Wild type HME or isogenic cells
carrying the
delE746-A750EGFR or the
E545KPIK3CA cancer alleles were glucose-starved for 5 hours. Cell were fixed and stained with a specific anti active,
not phosphorylated b-catenin antibody (Red) and DAPI (Blue) for the nuclear staining and analyzed by fluorescence microscopy. Graphs report the
percentage of b-catenin positive nuclei (average 6 SD of 10 different fields containing at least 40 cells/field. t-test, ***p,0.001, **p,0.01, *p,0.05).
The exposure time was kept constant through the images analysis. (F) b-catenin contributes to MnSOD promoter activation under GD. (Left graph)
Wild type HME cells were transfected with vectors expressing the indicated proteins together with a wild type MnSOD promoter luciferase-reporter
(23340+1MnSOD-luc), or with a mutant derivative which contains mutated FOXO binding sites (23340+1mutMnSOD-luc) and analyzed after 8 hours
of GD. Data represent means 6 SD derived from four independent experiments. (Right graph) Wild type HME cells or isogenic clones expressing the
delE746-A750EGFR or the E545KPIK3CA allele were transfected with vectors expressing the indicated proteins in presence of wild type MnSOD
promoter luciferase-reporter and analyzed after 8 hours of GD. Data represent means 6 SD. The efficiency of transfection was normalized by the
cotransfection of CMV-Renilla luciferase reporter.
doi:10.1371/journal.pone.0037526.g008
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b-catenin stability. We propose that the GSK3b, b-catenin and
MnSOD axis represents a potential target to lower the resistance




Flag-b-catenin, pMT2-HA-FOXO4, pSOD-luc(23340+1) and
the pSODmut-luc carrying point mutations in two FOXO binding
sites were a generous gift from Dr B.M. Burgering (University
Figure 9. The GSK3b/b-catenin/MnSOD axis promotes resistance to GD-induced cell death. (A) Wild type HME cells were cotransfected
with equal amounts of the indicated expression vectors. 24 hours after transfection, cells were glucose-starved for 48 hours and the percentage of
dead cells was quantified by FACS analysis of propidium iodide positive cells. Graphs report the average derived from three independent experiments
6 SD (t-test, **p,0.01). The inset shows an anti-HA immunoblot of total protein extracts from cells transfected with the HA-GSK3b or HA-
GSK3b(K85R) vectors and used for the GD experiments. b-actin was used as loading control. (B) Wild type HME cells stably transfected with an empty
vector (pcDNA#1 and pcDNA#2) or with an expression vector for MnSOD (MnSOD#1 and MnSOD#2) were exposed to GD for 60 hours and the
percentage of dead cells were quantified by FACS analysis of propidium iodide positive cells. At least three independent empty vector- or MnSOD-
transfected clones were analyzed and gave similar results. The inset represents an immunoblot analysis showing the expression of MnSOD in total
protein extracts from two representative clones used for the experiments. b-actin was used as loading control. Graphs report the average derived
from three independent experiments 6 SD (t-test, **p,0.01 or ***p,0.001, empty vector Vs MnSOD).
doi:10.1371/journal.pone.0037526.g009
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described elsewhere [24,26]. CMV-Renilla luciferase was pur-
chased from Promega. The pCDNA-MnSOD has been previously
described [47]. Expression plasmids for wild type GSK3b and
dominant-negative GSK3b(K85A) were purchased from Addgene.
Cell viability
Cell viability was determined by flow cytometry using
propidium iodide (PI) staining. Briefly, after the specific treat-
ments, detached and attached cells were collected, washed twice
with PBS 16and stained with propidium iodide; PI positive cells,
e.g. death cells, were detected by flow cytometry with a
FACSCalibur (Becton Dickinson) and analyzed by using the
CellQuest software (Becton Dickinson).
ATP quantification
Cells were counted and plated in a 96-well plate in quadrupli-
cates at the density of 3000 cells/well. After 48 hours, cells were
glucose-starved and harvested at different time points. ATP assay
was carried out using the ATPlite assay (Perkin Elmer) according
to the manufacturer’s instructions. A parallel experiment was
performed to determine the cell number by nuclei counting after
staining with 1 mg/ml Hoechst 33342. Nuclei were detected by
florescence microscopy with a BD pathway HT bioimager with
the AttoVision Acquisition Software Module and quantified by
using the BD Date Image Explorer Software.
GSH/GSSG measurement
Reduced and oxidized Glutathione ratio was measured by using
the GSH/GSSG-Glo assay kit (Promega) according to the
manufacturer’s protocol.
Quantitative Real-Time PCR
Total RNA extraction was done using Tryzol (Invitrogen)
according to the manufacturer’s instructions. Total RNA was then
reverse-transcribed into cDNA by using M-MLV Reverse
Transcriptase (Gibco BRL) with oligo random hexamers. The
cDNA was subjected to quantitative PCR analysis by using Light
Cycler (Applied Biosystem) with SYBR Green PCR Master MIX
Kit (Applied Biosystem). The primers sequences for the PCR
analysis are available on request.
Statistical analysis
Data are presented as mean 6 standard deviation (SD).
Statistical significance was analyzed by using, where appropriate,
a two-tailed Student’s t-test. P values less or equal than 0.05 were
considered statistically significant.
Additional experimental procedures (materials and reagents,
cell lines, cell culture and transfection, protein extracts, western
blot analysis, glycogen measurement, luciferase reporter assay and
immunoflorescence analysis) are provided as Methods S1.
Supporting Information
Figure S1 The insertion of oncogenic alleles by homol-
ogous recombination (knock-in) effectively and specifi-
cally affects the downstream signaling pathways in





mutations were treated with the indicated serum concentrations
for 16 hours. Equal amounts of total protein extracts were
analyzed by immunoblot with the indicated antibodies. ERK1/2
indicates the p42/p44 proteins; pERK1/2 indicates the Thr202
and Tyr204 phosphorylated residues of ERK1/2. pMEK1/2
indicates the phosphorylated residues at Ser217 and Ser221 of
MEK1/2. Data are representative of three independent experi-
ments that gave similar results.
(TIF)
Figure S2 HME clones carrying the
delE746-A750EGFR or
the
E545KPIK3CA allele are resistant to GD-induced cell
death. Additional HME clones carrying oncogenic mutations -
independently generated from clones presented in Figure 1 - were
glucose starved for 48 hours. The percentage of dead cells was
quantified by FACS analysis of propidium iodide positive cells.
Results report the data derived on the average from four
independent experiments 6 SD.
(TIF)
Figure S3 Phosphorylation of AMPKa(T172) in wild type
HME cells and in isogenic control knock-in cells. (A)
Additional HME clones carrying oncogenic mutations - indepen-
dently generated from clones presented in Figure 1 - were glucose
starved for 10 hours and equal amount of total protein extracts
were assayed by immunoblot with the indicated antibodies. (B)
Wild type HME and isogenic knock-in clones generated by
homologous recombination of the wild type EGFR or PIK3CA
alleles were treated and analyzed as in (A). The levels of
pAKT(S437) on the same protein extracts are also reported
showing that the activation of the PI3K-dependent pathways is
comparable in all three clones.
(TIF)
Figure S4 Upregulation of MnSOD by EGFR or PIK3CA




were glucose starved for the indicated hours. Total proteins were
extracted and analyzed by immunoblot with the indicated
antibodies. The graph reports the densitometry analysis of the
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